Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Blinded, Placebo-Controlled, Safety, Tolerability and PK Study of GS-6207 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Blinded, Placebo-Controlled, Safety, Tolerability and PK Study of GS-6207 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenacapavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 04 Jul 2020 According to a Gilead Sciences media release, data from this trial were presented at the at the 23rd International AIDS Conference (AIDS 2020: Virtual).
    • 04 Jul 2020 Results (n=30) presented in a Gilead Sciences media release.
    • 01 Jul 2020 According to a Gilead Sciences media release, data from this trial will be presented at the at the 23rd International AIDS Conference (AIDS 2020: Virtual).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top